Goals
- To serve as a common platform and forum for the discussion of various pre-clinical translational ideas with a high likelihood of being developed into clinical trial concepts, including evaluation of conventional Phae I - II endpoints, but also including development of novel endpoints, biomarker incorporation, compartmental disease control, novel imaging, patient reported outcomes including quality of life, and neurocognitive function.
- To assist the NCI disease-specific and other Interest Groups specifically in terms of evaluating concepts for brain metastases and GBM.
BM-GBM Interest Group Chairpersons
Brain Metastasis Group
Michelle Kim, M.D., University of Michigan: michekm@med.umich.edu
Minesh Mehta, M.D., FASTRO Miami Cancer Institute: mineshm@baptishealth.net
GBM Subgroup
Rupesh Kotecha, M.D., Miami Cancer Institute: rupeshk@baptisthealth.net
Evanthia Galanis, M.D., Mayo Clinic Rochester galanis.evanthia@mayo.edu
Minesh Mehta, M.D., FASTRO Miami Cancer Institute: mineshm@baptisthealth.net
Teleconference Schedule
The BM-GBM group meets through WebEx on the last Monday of each month at 5:00 p.m. ET, with alternating topics relating to brain metastasis and GBM. Group membership is approximately 65.
Activities and Accomplishments
Clinical Trials
- Testing the safety of M6620 (VX-970) when given with standard whole brain radiation therapy for the treatment of Brain Metastases from Non-Small Cell Lung Cancer. Small Cell Lung Cancer or Neuroendocrine Tumors (clinicaltrials.gov identifiers: NCT02589522)
- Ropidoxuridine and Whole Brain Radiation Therapy in treating patients with Brain Metastases. (clinicaltrials.gov identifier: NCT02993146)
- T-DM1 Alone versus T-DM1 and Metronomic Temozolomide in secondary prevention of HERS2 - positive breast cancer Brain Metastases following Stereotactic Radiosurgery. (clinicaltrials.gov identifier: NCT03190967)
- Nivolumab, BMS-986205, and Radiation Therapy with or without Temozolomide in treating patients with newly diagnosed Glioblastoma. (clinicaltrials.gov identifier: NCT04047706)
- Testing the use of the Immunotherapy Drugs Ipilimumab and Nivolumab plus Radiation Therapy compared to the usual treatment (Temozolomide and Radiation Therapy), for newly diagnosed MGMT unmethylated Glioblastoma. (clinicaltrials.gov identifier: NCT04396860)
Publications
- R.S. Bindra, E. Galanis, M.P. Mehta, State of the Art: The Evolving Role of RT in Combined Modality Therapy for GBM, J. Neurooncol, 134 (2017) 477-478 DOI: 10.1007/s 11060-017-2596-4
- C.A. Kunos, E. Galanis, J. Buchsbaum, Q. Shi. et/al, Radiation-agent Combinations for Glioblastoma Challenges in Drug Development and Future Considerations. J. Neurooncol, 134 (2017) 551-557, DOI: 10.1007/s11060-017-2458-0
Workshops
- M.M. Kim, M.P. Mehta, D.K. Samrt, et.al., National Cancer Institute collaborative workshop on Shaping the Landscape of Brain Metastases Research: Challenges and Recommended Priorities, Lancet Oncol 2023, 24:344-54, DOI: 10.1016/S1470-2045(23)00297-8
- NCI Brain Metastases follow-up workshop, October 8, 2024, NCI Shady Grove Campus, Rockville, Maryland
Interested in becoming a member of the BM-GBM Interest Group?
Please contact the Interest Group Coordinator:
J. Manuel Perez, Ph.D.
Radiation Research Program,
Division of Cancer Research and Diagnosis
National Cancer Institute
jmanuel.perez@nih.gov